Bupropion for the treatment of methamphetamine dependence in non-daily users: A randomized, double-blind, placebo-controlled trial

Highlights • Bupropion SR 150 mg BID, vs. matched placebo, for 12 weeks to 204 treatment-seekers. • 3× per week urines for meth and bupropion levels. No biomarker for placebo. • No significant difference between treatment groups in % abstinent in Weeks 11–12. • Bupropion adherence per protocol was a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Drug and alcohol dependence 2015-05, Vol.150, p.170-174
Hauptverfasser:	Anderson, Ann L, Li, Shou-Hua, Markova, Denka, Holmes, Tyson H, Chiang, Nora, Kahn, Roberta, Campbell, Jan, Dickerson, Daniel L, Galloway, Gantt P, Haning, William, Roache, John D, Stock, Christopher, Elkashef, Ahmed M
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Amphetamine-Related Disorders - drug therapy Amphetamine-Related Disorders - psychology Amphetamine-Related Disorders - therapy Bupropion Bupropion - therapeutic use Dopamine Uptake Inhibitors - therapeutic use Double-Blind Method Drug therapy Female Humans Male Medication Adherence Methamphetamine Methamphetamine - urine Patient acuity Psychiatry Psychotherapy, Group Substance-related disorders Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Bupropion SR 150 mg BID, vs. matched placebo, for 12 weeks to 204 treatment-seekers. • 3× per week urines for meth and bupropion levels. No biomarker for placebo. • No significant difference between treatment groups in % abstinent in Weeks 11–12. • Bupropion adherence per protocol was achieved by just 47%. • Additional data show wide range of adherence patterns, max levels, and clearance rates.
ISSN:	0376-8716 1879-0046
DOI:	10.1016/j.drugalcdep.2015.01.036